$BEGI Management — respectfully, shareholders need clarity and execution.
Dilution without real momentum is concerning. If current strategy isn’t working, consider partnerships, shareholder-aligned actions, or even a merger/sale to unlock value.
We need results, not promises.
$BEGI long, high avg — patience tested. Watching other plays move while this stays quiet. Not bashing, just honest. Need updates, progress, or action to restore confidence. Even a buyback or strategic moves would show commitment. Still here… waiting
Tired $GRLT long here — high avg and patience wearing thin on this grind. Still believe in the RWA long-term story, but we need real progress: ticker update, news flow, or shareholder value moves. Even a buyback would show conviction. Hoping the turnaround finally comes.
$BEGI has been quietly checking boxes — lawsuit resolved, platform presented, strategic interest building.
Now it’s about filings, not tweets.
Watching January closely. 👀📄
#BEGI
Dear Big Pharma:
$RSPI isn’t just another biotech — CX1739 has DoD-linked work, and the GABAkine platform just earned NIH/NINDS funding.
Real science. Real potential.
Grab a bargain before Phase 2 readouts or a licensing deal hits. 🎁
@Pfizer@JNJ@Novartis@Merck@BristolMyers
$BEGI holds patents to trade stocks, crypto, and other digital assets on blockchain 👀💡 Fintech & trading strategists, are you paying attention? Sometimes the quietest tickers hide the most under-explored potential. Who’s watching 😉
@CoinDesk@ARKInvest@BlackRock#Blockchain
$MCET hasn’t made noise in years, but forgotten biotech IP sometimes ends up being more valuable than people realize. With the right strategic guidance or fresh leadership interest, even dormant assets can find a second life. #Biotech#PatentLaw#IP
$BEGI is one of those quiet tickers with interesting historical IP roots. The right catalyst or management update could change the whole narrative fast